MST Continus granules to be discontinued

All strengths of MST Continus (morphine) prolonged-release granules for oral suspension are being discontinued because of difficulty sourcing a key excipient.

MST Continus granules are licensed for the prolonged relief of severe and intractable pain. | GETTY IMAGES
MST Continus granules are licensed for the prolonged relief of severe and intractable pain. | GETTY IMAGES

Alternative morphine presentations, both prolonged-release and immediate-release, remain available and will be able to support increased demand.

Anticipated out of stock dates for MST Continus granules are as follows:

  • 20mg granules - November 2021
  • 30mg granules - August 2021
  • 60mg granules - June 2021
  • 100mg granules - May 2021
  • 200mg granules - January 2022

Healthcare professionals should not initiate MST Continus in new patients. Individuals currently prescribed MST Continus granules should be contacted for a treatment review.

For patients with swallowing difficulties or who are being tube fed, Zomorph (administered twice daily) and MXL capsules (administered once daily) are potential alternative modified-release morphine preparations. Further guidance can be found in the CAS alert.

When other modified-release morphine preparations are not appropriate, clinicians should consider prescribing:

  • standard-release morphine preparations with as-required pain relief for breakthrough pain;
  • opioid transdermal patches with as-required pain relief for breakthrough pain (in patients whose pain control has been stabilised); or
  • other oral opioids (eg, oxycodone), if appropriate.

Care should be taken to ensure correct dose conversion when switching from MST Continus to standard-release morphine preparations or to alternative opioid products. Equivalence tables should be used as a guide as individual responses may vary. Patients should be monitored for signs of opioid toxicity and loss of pain control following any switch in therapy.

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in